Advertisement

Use of Erythropoietin in Critically Ill Patients

  • A. Gabriel
  • M. Zimpfer
Conference paper

Abstract

Critically ill patients frequently suffer from the systemic inflammatory response syndrome (SIRDS) as a consequence of major insults to the organism [1]. SIRDS is commonly associated with anemia [2] and anemia has been shown to aggravate already impaired tissue O2 availability in sepsis [3]. As tissue O2 availability influences survival [2], the logic of normalizing hemoglobin concentrations has frequently been argued [4, 5] . Exogenous administration of recombinant human erythropoietin (rhuEPO) is one component of the blood conservation program [6] in critically ill ICU patients. In the following we want to describe the characteristics of the anemia of inflammatory diseases, the role of endogenously produced erythropoietin (EPO), as well as the efficacy of exogenous administration of the available human recombinant form of this growth factor.

Keywords

Erythroid Progenitor Erythropoietin Production Serum Erythropoietin Level Post Bone Marrow Transplantation Erythropoietin Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778PubMedCrossRefGoogle Scholar
  2. 2.
    Shoemaker WC, Appel PL, Kram HB et al (1988) Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients. Chest 94:1176–1186PubMedCrossRefGoogle Scholar
  3. 3.
    Sibbald WJ, Bloos F, Morisaki H (1996) Sepsis, Anemia, and Tissue O2 Availability. In: Vincent J-L (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin Heidelberg New York, pp 287–295CrossRefGoogle Scholar
  4. 4.
    Cane RD (1990) Hemoglobin: How much is enough? Crit Care Med 18:1046PubMedCrossRefGoogle Scholar
  5. 5.
    Welch GH, Meehan KR, Goodnough LT (1992) Prudent strategies for elective red blood cell transfusion. Ann Intern Med 116:393PubMedCrossRefGoogle Scholar
  6. 6.
    Chernow B (1993) Blood conservation in critical care — The evidence accumulates. Crit Care Med 21(4):481–482PubMedCrossRefGoogle Scholar
  7. 7.
    Krantz SB (1994) Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307(5):353–359PubMedCrossRefGoogle Scholar
  8. 8.
    Means R Jr, Dessypris EN, Krantz SB (1992) Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. Journal of Cellular Physiology 150 (1):59–64PubMedCrossRefGoogle Scholar
  9. 9.
    Maury CP, Andersson LC, Teppo AM et al (1988) Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro. Annals of the Rheumatic Diseases 47(12):972–978PubMedCrossRefGoogle Scholar
  10. 10.
    Roodman GD, Bird A, Hutzler D et al (1987) Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Experimental Hematology 15 (9):928–935PubMedGoogle Scholar
  11. 11.
    Akahane K, Hosoi T, Urabe A et al (1987) Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. International Journal of Cell Cloning 5(1):16–26PubMedCrossRefGoogle Scholar
  12. 12.
    Means R Jr, Krantz SB (1993) Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. Journal of Clinical Investigation 91(2):416–419PubMedCrossRefGoogle Scholar
  13. 13.
    Zoumbos NC, Djeu JY, Young NS (1984) Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. Journal of Immunology 133(2):769–774Google Scholar
  14. 14.
    Raefsky EL, Platanias LC, Zoumbos NC et al (1985) Studies of interferon as a regulator of hematopoietic cell proliferation. Journal of Immunology 135(4):2507–2512Google Scholar
  15. 15.
    Mamus SW, Beck-Schroeder S, Zanjani ED (1985) Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. Journal of Clinical Investigation 75(5):1496–1503PubMedCrossRefGoogle Scholar
  16. 16.
    Tarumi T, Sawada K, Sato N et al (1995) Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 23(12):1310–1318PubMedGoogle Scholar
  17. 17.
    Wilder RL, Lafyatis R, Roberts AB et al (1990) Transforming growth factor-beta in rheumatoid arthritis. Annals of the New York Academy of Sciences 593:197–207PubMedCrossRefGoogle Scholar
  18. 18.
    Keller JR, Sing GK, Ellingsworth LR et al (1990) Two forms of transforming growth factorbeta are equally potent selective growth inhibitors of early murine hematopoiesis. Annals of the New York Academy of Sciences 593:172–180PubMedCrossRefGoogle Scholar
  19. 19.
    Gogu SR, Malter JS, Agrawal KC (1992) Zidovudine-induced blockade of the expression and function of the erythropoietin receptor. Biochem Pharmacol 44(6):1009–1012PubMedCrossRefGoogle Scholar
  20. 20.
    Spivak JL, Barnes DC, Fuchs E et al (1989) Serum immunoreactive erythropoietin in HIVinfected patients. Jama 261(21):3104–3107PubMedCrossRefGoogle Scholar
  21. 21.
    Camacho J, Poveda F, Zamorano AF et al (1992) Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection. Br J Haematol 82(3): 608–614PubMedCrossRefGoogle Scholar
  22. 22.
    Eckardt KU (1996) Erythropoietin production in liver and kidneys. Curr Opin Nephrol Hypertens 5(1):28–34PubMedCrossRefGoogle Scholar
  23. 23.
    Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68(5):215–223PubMedCrossRefGoogle Scholar
  24. 24.
    Radtke HW, Claussner A, Erbes PM et al (1979) Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 54(4):877–884PubMedGoogle Scholar
  25. 25.
    Ward HP, Kurnick JE, Pisarczyk MJ (1971) Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J Clin Invest 50(2):332–335PubMedCrossRefGoogle Scholar
  26. 26.
    Zucker S, Lysik R (1974) Bone marrow erythropoiesis in anemia of inflammation. J Lab Clin Med 84(5):620–631PubMedGoogle Scholar
  27. 27.
    Boyd HK, Lappin TR (1991) Erythropoietin deficiency in the anemia of chronic disorders. Eur J Haematol 46(4):198–201PubMedCrossRefGoogle Scholar
  28. 28.
    Lapinsky SE, Baynes RD, Schulz EJ et al (1992) Anemia, iron-related measurements and erythropoietin levels in untreated patients with active leprosy. J Intern Med 232(3):273–278PubMedCrossRefGoogle Scholar
  29. 29.
    Baer AN, Dessypris EN, Goldwasser E et al (1987) Blunted erythropoietin response to anemia in rheumatoid arthritis. British Journal of Haematology 66(4):559–564PubMedCrossRefGoogle Scholar
  30. 30.
    Urabe A, Mitani K, Yoshinaga K et al (1992) Serum erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning 10(6):333–337PubMedCrossRefGoogle Scholar
  31. 31.
    Beguin Y, Yerna M, Loo M et al (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82(4):648–653PubMedCrossRefGoogle Scholar
  32. 32.
    Miller CB, Jones RJ, Piantadosi S et al (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322(24):1689–1692PubMedCrossRefGoogle Scholar
  33. 33.
    Birgegard G, Wide L, Simonsson B (1989) Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anemia for stimulation. Br J Haematol 72(3):462–466PubMedCrossRefGoogle Scholar
  34. 34.
    Abedi MR, Backman L, Bostrom L et al (1990) Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 6(2):121–126PubMedGoogle Scholar
  35. 35.
    Bosi A, Vannucchi AM, Grossi A et al (1991) Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica 76(4):280–284PubMedGoogle Scholar
  36. 36.
    Vannucchi AM, Grossi A, Bosi A et al (1991) Impaired erythropoietin production in mice treated with cyclosporin A. Blood 78(6):1615–1618PubMedGoogle Scholar
  37. 37.
    Phibbs RH, Shannon KM, Mentzer WC (1992) Potential for treatment of anemia of prematurity with recombinant human erythropoietin: preliminary results. Acta Haematol 1:28–33CrossRefGoogle Scholar
  38. 38.
    Christensen RD, Hunter DD, Goodell H et al (1992) Evaluation of the mechanism causing anemia in infants with bronchopulmonary dysplasia. J Pediatr 120(4 Pt 1):593–598PubMedCrossRefGoogle Scholar
  39. 39.
    Sherwood JB, Goldwasser E, Chilcote R et al (1986) Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood 67(1):46–49PubMedGoogle Scholar
  40. 40.
    Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79(8):1987–1994PubMedGoogle Scholar
  41. 41.
    Jelkmann W, Pagel H, Wolff M et al (1992) Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sciences 50(4):301–308PubMedCrossRefGoogle Scholar
  42. 42.
    Henry DH, Beall GN, Benson CA et al (1992) Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 117(9):739–748PubMedCrossRefGoogle Scholar
  43. 43.
    Singh A, Eckardt KU, Zimmermann A et al (1993) Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91(1):251–256PubMedCrossRefGoogle Scholar
  44. 44.
    Schapira L, Antin JH, Ransil BJ et al (1990) Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76(11):2354–2359PubMedGoogle Scholar
  45. 45.
    Wolff M, Jelkmann W (1993) Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 66(1):27–31PubMedCrossRefGoogle Scholar
  46. 46.
    Spahn DR, Pasch T (1996) Critical Hematocrit. In: Vincent J-L (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin Heidelberg New York, pp 635–642CrossRefGoogle Scholar
  47. 47.
    Walker RH (1987) Special report: transfusion risks. American Journal of Clinical Pathology 88(3):374–378PubMedGoogle Scholar
  48. 48.
    Mickler TA, Longnecker DE (1992) The immunosuppressive aspects of blood transfusion. J Intensive Care Med 7(4):176–188Google Scholar
  49. 49.
    Lanzer G, Vadon M (1991) Immunologische Aspekte der Fremdbluttransfusion. In: List WF GH (ed) Beitraege zur Anaesthesiologie, Intensiv- und Notfallmedizin 39. Verlag Wilhelm Maudrich, Wien Muenchen Bern, pp 15–23Google Scholar
  50. 50.
    Blumberg N, Heal M (1989) Transfusion and recipient immune function. Archs Pathol Lab Med 113:246–253Google Scholar
  51. 51.
    Means R Jr, Olsen NJ, Krantz SB et al (1989) Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis & Rheumatism 32(5):638–642CrossRefGoogle Scholar
  52. 52.
    Pincus T, Olsen NJ, Russell IJ et al (1990) Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. American Journal of Medicine 89(2): 161–168PubMedCrossRefGoogle Scholar
  53. 53.
    Birgegard G, Gudbjronsson B, Hallgren R et al (1991) Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. Contributions to Nephrology 88:295–303PubMedGoogle Scholar
  54. 54.
    Oster W, Herrmann F, Gamm H et al (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. Journal of Clinical Oncology 8(6):956–562PubMedGoogle Scholar
  55. 55.
    Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322(24):1693–1699PubMedCrossRefGoogle Scholar
  56. 56.
    Fischl M, Galpin JE, Levine JD et al (1990) Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322(21):1488–1493PubMedCrossRefGoogle Scholar
  57. 57.
    Tauchi T, Ohyashiki JH, Fujieda H et al (1990) Correction of anemia in rheumatoid arthritis by recombinant human erythropoietin. Br J Rheumatol 29(3):235–236PubMedCrossRefGoogle Scholar
  58. 58.
    Pavlovic-Kentera V, Clemons GK, Biljanovic-Paunovic L et al (1992) Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin. Biomed Pharmacother 46(1):37–43PubMedCrossRefGoogle Scholar
  59. 59.
    Locatelli F, Pedrazzoli P, Barosi G et al (1992) Recombinant human erythropoietin is effective in correcting erythropoietin-defiicient anemia after allogenejc bone marrow transplantation. Br J Haematol 80(4):545–549PubMedCrossRefGoogle Scholar
  60. 60.
    Krantz SB, Wolfe F, Russell IJ et al (1991) Recombinant human erythropoietin (Epoetin Alpha) in patients with the anemia of chronic disease. In: Erslev AJ, Adamson JW, Eschbach JW, Winearls CG (ed) Erythropoietin, Molecular, Cellular and Clinical Biology. The Johns Hopkins University Press, Baltimore, pp 404–418Google Scholar
  61. 61.
    Means R Jr, Krantz SB (1991) Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 78(10):2564–2567PubMedGoogle Scholar
  62. 62.
    Casadevall N, Belanger C, Goy A et al (1992) High-dose recombinant human erythropoietin administered intravenously for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 1:25–27CrossRefGoogle Scholar
  63. 63.
    Cazzola M, Ponchio L, Beguin Y et al (1992) Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79(1):29–37PubMedGoogle Scholar
  64. 64.
    Platanias LC, Miller CB, Mick R et al (1991) Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9(11):2021–2026PubMedGoogle Scholar
  65. 65.
    Stenke L, Wallvik J, Celsing F et al (1993) Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7(9):1324–1327PubMedGoogle Scholar
  66. 66.
    Taniguchi S, Yamasaki K, Shibuya T et al (1993) Recombinant human erythropoietin for longterm persistent anemia after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant 12(4):423PubMedGoogle Scholar
  67. 67.
    Gamucci T, Thorel MF, Frasca AM et al (1993) Erythropoietin for the prevention of anemia in neoplastic patients treated with cisplatin. Eur J Cancer 40400(1085):1976Google Scholar
  68. 68.
    Byrd TF, Horwitz MA (1993) Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. J Clin Invest 91(3):969–976PubMedCrossRefGoogle Scholar
  69. 69.
    Fuchs D, Hausen A, Reibnegger G et al (1988) Neopterin as a marker for activated cellmediated immunity: application in HIV infection. Immunol Today 9(5):150–155PubMedCrossRefGoogle Scholar
  70. 70.
    Denz H, Fuchs D, Huber H et al (1990) Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. European Journal of Haematology 44(3):186–189PubMedCrossRefGoogle Scholar
  71. 71.
    Wachter H, Fuchs D, Hausen A et al (1989) Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Advances in Clinical Chemistry 27: 81–141PubMedCrossRefGoogle Scholar
  72. 72.
    Danielson B (1995) rhuEPO hyporesponsiveness — who and why? Nephrol Dial Transplant 2:69–73CrossRefGoogle Scholar
  73. 73.
    Rogers J, Lacroix L, Durmowitz G et al (1994) The role of cytokines in the regulation of ferritin expression. Adv Exp Med Biol 356:127–132PubMedCrossRefGoogle Scholar
  74. 74.
    Moldawer LL, Marano MA, Wei H et al (1989) Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. Faseb J 3(5):1637–1643PubMedGoogle Scholar
  75. 75.
    Alvarez-Hernandez X, Liceaga J, McKay IC et al (1989) Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 61(3): 319–322PubMedGoogle Scholar
  76. 76.
    Means R Jr, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80(7):1639–1647PubMedGoogle Scholar
  77. 77.
    Gabriel A, Kozek S, Chiari A et al (1996) High dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma, submittedGoogle Scholar
  78. 78.
    Singbartl G (1994) Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest Suppl 72(6):S36-S43Google Scholar
  79. 79.
    Poletes GP, Miller SF, Finley RK et al (1994) Blood use in the bum unit: a possible role for erythropoietin. J Burn Care Rehabil 15(1):37–41PubMedCrossRefGoogle Scholar
  80. 80.
    Deitch EA, Sittig KM (1993) A serial study of the erythropoietic response to thermal injury. Ann Surg 217(3):293–299PubMedCrossRefGoogle Scholar
  81. 81.
    Vasko SD, Burdge JJ, Ruberg RL et al (1991) Evaluation of erythropoietin levels in the anemia of thermal injury. J Bum Care Rehabil 12(5):437–441CrossRefGoogle Scholar
  82. 82.
    Still J Jr, Belcher K, Law EJ et al (1995) A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 38(2):233–236PubMedCrossRefGoogle Scholar
  83. 83.
    Vaziri ND, Eltorai IM, Segal J et al (1993) Erythropoietin profile in spinal cord injured patients. Arch Phys Med Rehabil 74(1):65–67PubMedGoogle Scholar
  84. 84.
    Kraus P, Lipman J (1992) Erythropoietin in a patient following multiple trauma. Anaesthesia 47(11):962–964PubMedCrossRefGoogle Scholar
  85. 85.
    Finfer S, Howell S, Miller J et al (1994) Major trauma in two patients refusing blood transfusion. Br Med J 308(6941):1423–1424CrossRefGoogle Scholar
  86. 86.
    Donner B, Tryba M, Kurz-Muller K et al (1996) Anaesthesia and intensive care management of severely burned children of Jehovah’s witnesses. Anaesthesist 45(2):171–175PubMedCrossRefGoogle Scholar
  87. 87.
    Komowski R, Schwartz D, Jaffe A et al (1992) Erythropoietin therapy obviates the need for recurrent transfusions in a patient with severe hemolysis due to prosthetic valves. Chest 102(1):315–316CrossRefGoogle Scholar
  88. 88.
    Wardrop CA, Holland BM (1995) Recombinant haemopoietic growth factors in the newborn — will they be useful? Eur J Pediatr 154[8 Suppl 3]:513–514Google Scholar
  89. 89.
    Bifano EM, Curran TR (1995) Minimizing donor blood exposure in the neonatal intensive care unit: Current trends and future prospects. Clin Perinatol 22(3):657–669PubMedGoogle Scholar
  90. 90.
    Shannon KM, Mentzer WC, Abels RI et al (1992) Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: A pilot study. J Pediatr 120(4):586–592PubMedCrossRefGoogle Scholar
  91. 91.
    Salvado GA, Scherer SS, Valdebenito CC et al (1994) Human recombinant erythropoietin in preterm newborn infants. Rev Chil Pediatr 65(1):28–31Google Scholar
  92. 92.
    Fernandes CJ, Hagan R, Frieberg A et al (1994) Erythropoietin in very preterm infants. J Paediatr Child Health 30(4):356–359PubMedCrossRefGoogle Scholar
  93. 93.
    Krafte-Jacobs B, Levetown ML, Bray GL et al (1994) Erythropoietin response to critical illness. Crit Care Med 22(5):821–826PubMedCrossRefGoogle Scholar
  94. 94.
    Chao NJ, Schriber JR, Long GD et al (1994) A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 83(10):2823–2828PubMedGoogle Scholar
  95. 95.
    Binet JL, Fenaux P, Morel P et al (1993) Treatment of chronic lymphocytic leukaemia. Bailliere’s Clin Haematol 6(4):867–878CrossRefGoogle Scholar
  96. 96.
    Hortobagyi GN (1995) Management of breast cancer: Status and future trends. Semin Oncol 22(5):101–107Google Scholar
  97. 97.
    George MJ (1994) The present and future of hematopoietic cytokines in clinical practice. Stem Cells 12:249–255PubMedCrossRefGoogle Scholar
  98. 98.
    Meden H, Conrad A, Rath W (1993) New oncological therapy approaches with haematopoietic growth factors. Geburtshilfe Frauenheilkd 53(4):222–229PubMedCrossRefGoogle Scholar
  99. 99.
    Rowe JM, Rapoport AP (1992) Hemopoietic growth factors: A review. J Clin Pharmacol 32(6):486–501PubMedCrossRefGoogle Scholar
  100. 100.
    Seeger RC, Reynolds CP (1991) Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38(2):393–424PubMedGoogle Scholar
  101. 101.
    Gadner H, Haas OA (1992) Experience in pediatric myelodysplastic syndromes. Hematol Oncol Clin North Am 6(3):655–672PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • A. Gabriel
  • M. Zimpfer

There are no affiliations available

Personalised recommendations